1444P Real-world nivolumab safety data from 650 patients with unresectable advanced or recurrent gastric cancer that had progressed after cancer chemotherapy: Summary of post-marketing surveillance in Japan

Abstract

Nivolumab, an anti-PD-1 antibody, was approved in 2017 as a treatment for unresectable advanced or recurrent gastric cancer that had progressed following ≥2 lines of chemotherapy. Subsequently, post-marketing surveillance was implemented to collect real-world safety and efficacy data. This is the first real-world data on immune checkpoint inhibitors from >600 gastric cancer patients.